Endovascular Engineering, Inc.
PrivateLast Round
Series C
Apr 7, 2026
Est. Valuation
$70M
Total Funding Raised
$137.3M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Endovascular Engineering, Inc. operates in Healthcare & Life Sciences and is based in Menlo Park, California. Its latest recorded funding round was a Series C round in April 2026.
Endovascular Engineering, Inc. is a medical technology company that develops and deploys next-generation clot removal technologies targeting venous thromboembolism.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Endovascular Engineering, Inc. Comparables
Compare Endovascular Engineering, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Jupiter Endovascular | 89% | |
| Inquis Medical | 84% | |
| Thrombolex, Inc. | 84% |
For institutional investors. Book with your work email.
Endovascular Engineering, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Apr 7, 2026 | ||||
| Series B | Feb 18, 2025 | ||||
| Series A Extension | Apr 5, 2022 | ||||
| Grant | Sep 20, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Endovascular Engineering, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Philips Ventures | Series B |
| NIH RADx | Grant |
| 415 Capital | Series C, Series B |
| Gilde Healthcare | Series C |
| Santé Ventures | Series C, Series B, Series A Extension |
| Norwest Venture Partners | Series C |
| Panakès Partners | Series C, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 30, 2026
Grew 32% QoQ, from 41 to 54 employees.
- Jul 18, 2026
Grew 31% QoQ, from 39 to 51 employees.
For institutional investors. Book with your work email.
Endovascular Engineering, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Endovascular Engineering, Inc.'s valuation, stock price, and market status.
Is Endovascular Engineering, Inc. a public or private company?
Endovascular Engineering, Inc. is a private company.
What is the current stock price of Endovascular Engineering, Inc.?
Endovascular Engineering, Inc. is a private company, so its shares have no public market price. Caplight tracks Endovascular Engineering, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Endovascular Engineering, Inc. worth (valuation)?
Endovascular Engineering, Inc.'s valuation is estimated at $70.0M based on funding round data.
Can I buy Endovascular Engineering, Inc. stock?
Endovascular Engineering, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Endovascular Engineering, Inc.'s last funding round?
Endovascular Engineering, Inc.'s most recent funding round was Series C on April 7, 2026.
Who are the main investors in Endovascular Engineering, Inc.?
Key investors in Endovascular Engineering, Inc. include 415 Capital, Gilde Healthcare, Santé Ventures, Norwest Venture Partners, S3 Ventures.
Will Endovascular Engineering, Inc. IPO soon?
No public IPO plans have been announced for Endovascular Engineering, Inc..
How can I track Endovascular Engineering, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Endovascular Engineering, Inc.'s shares on secondary markets.